GH1 and brain neoplasm: In the general population, the diagnosis of GHD typically requires failing dynamic tests using two different secretagogues; however, in CCS exposed to cranial radiotherapy and individuals with a history of a brain tumor close to the hypothalamus/pituitary, failing one test was considered sufficient in the consensus guidelines published by the Growth Hormone Research Society (23).